



Dkt. 57155-AA/JPW/MJW

1646  
JPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Christophe P.G. Gerald, et al.  
Serial No.: 09/866,248 Examiner: J. F. Murphy  
Filed: May 25, 2001 Group Art Unit: 1646  
For: DNA ENCODING MAMMALIAN NEUROPEPTIDE FF (NPFF)  
RECEPTORS AND USES THEREOF

1185 Avenue of the Americas  
New York, New York 10036  
June 25, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

RESPONSE TO JUNE 4, 2004 OFFICE ACTION

This Response is submitted in reply to the June 4, 2004 Office Action issued in connection with the above-identified application. A response to the June 4, 2004 Office Action is due July 4, 2004. Accordingly, this Response is being timely filed.

Restriction Requirement Under 35 U.S.C. §121

On page 2 of the November 17, 2003 Office Action, the Examiner to whom the subject application is assigned required restriction under 35 U.S.C. §121 to one of the following allegedly independent and distinct inventions:

- I. Claims 183-191, drawn to a process for preparing an agonist or antagonist of the rat NPFF1 receptor of SEQ ID NO:2, ATCC Deposit Number 203184, classified in class 435, subclass 7.2;
- II. Claims 183-191, drawn to a process for preparing an agonist

Applicants: Christophe P.G. Gerald, et al.  
Serial No.: 09/866,248  
Filed: May 25, 2001  
Page 2

or antagonist of the human NPFF1 receptor of SEQ ID NO:4,  
ATCC Deposit Number 203183, classified in class 435,  
subclass 7.2;

III. Claims 183-191, drawn to a process for preparing an agonist  
or antagonist of the human NPFF2 receptor of SEQ ID NO:6,  
ATCC Deposit Number 203255, classified in class 435,  
subclass 7.2;

IV. Claims 183-191, drawn to a process for preparing an agonist  
or antagonist of the human NPFF1 receptor of SEQ ID NO:8,  
ATCC Deposit Number 203605, classified in class 435,  
subclass 7.2.

In response to this restriction requirement, applicants elect,  
without traverse, Group III, i.e. claims 183-191 directed to a  
process for preparing an agonist or antagonist of the human NPFF2  
receptor.


Applicants maintain that claims 183-191 define a single inventive  
concept and respectfully request that the Examiner reconsider and  
withdraw his restriction requirement and examine claims 183-191  
as to all four Groups, and at a minimum as to at least Group IV  
as well as elected Group IV.

If a telephone interview would be of assistance in advancing  
prosecution of the subject application, applicants' undersigned  
attorney invites the Examiner to telephone him at the number  
provided below.

Applicants: Christophe P.G. Gerald, et al.  
Serial No.: 09/866,248  
Filed: May 25, 2001  
Page 3

No fee is deemed necessary in connection with the filing of this Response. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.


Respectfully submitted,



John P. White  
Registration No. 28,678  
Attorney for Applicants  
Cooper & Dunham LLP  
1185 Ave of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this  
correspondence is being deposited  
this date with the U.S. postal  
Service with sufficient postage as  
first class mail in an envelope  
addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

 6/25/04  
John P. White Date  
Reg. No. 28,678